Enabling Advanced Cell Therapies (ENACT): Invitation to an Online Forum on Resolving Barriers to Clinical Translation
Tania Bubela(Simon Fraser University), Chris Mason(Oak Ridge National Laboratory), Judy Illes(University of British Columbia), Emily J Culme-Seymour(GlaxoSmithKline (United Kingdom)), Ubaka Ogbogu(University of Alberta), Amir Reshef(University of Alberta), Matthew Li(Harvard University), Timothy Caulfield(University of Alberta), Rosario Isasi(Stem Cell Institute), James M. Piret(University of British Columbia), Christopher McCabe(University of Leeds), E. Richard Gold(McGill University), Harold Atkins(State University of New York)
Cited by 5
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
BTRFS
|ACM Transactions on Storage|2013|381
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
|The Lancet|2019|287
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
Cell-based therapeutic strategies for multiple sclerosis
|Brain|2017|169